Core One Labs flagship product CannaStrips ™ lands in eight new stores
Vancouver, British Columbia, November 12, 2019 / CNW / – Core One Labs Inc. (CSE: COOL), (OTCQX: CLABF), (Frankfurt: LD6, WKN: A14XHT) (“COOL” or the “Company”) announces that its new non-exclusive distribution partner, Fenix ââLogistics, has delivered CannaStripsMT in eight new stores bringing the total of CannaStrips storesMT were delivered to 50.
CannaStripsMT is COOL’s innovative oral strip for effective delivery to the oral mucosa that changes the way people consume cannabis. CannaStripsMT were recently distributed by DYME Distribution (“DYME”) which had a sales team covering the entire state of California. In a recent article published by DYME’s parent company, DYME announced a reduction in the number of employees in order to restructure the company in the future. COOL has decided on a non-exclusive distribution effort with Fenix ââLogistics outside of Sacramento, California (“Fenix”) to distribute the Company’s two brands, RÃªveur and CannaStripsMT. Fenix ââcovers over 150 retail stores and delivery companies with seven sales representatives and has already landed CannaStripsMT in eight new stores. This is in addition to stores already offering both RÃªveur and CannaStrips.MT products on their shelves.
The President of the Company, Casey Fenwick, said: âIt’s a good transition for the COOL brands. Fenix ââoffers sales, distribution and marketing services, which will make our brands look and feel congruent when presented in a face-to-face in-store situation as well as in promotional marketing material on social media or in print. In addition to distribution and marketing services, we are discussing the possibility of Fenix ââassisting COOL in distributing the company’s outdoor crop when these services are required. “
CannaStripsMT is an oral strip formulated for effective delivery to the oral mucosa that disrupts the barrier created by saliva covering the mucous membrane for active materials (in this case cannabinoids) that have been nanoparticulate and encapsulated to penetrate multiple layers of mucous membranes and submucosa for blood circulation. Once in the bloodstream, the encapsulation is undetectable as foreign material by the liver. This undetectability allows the material to avoid being filtered out of the bloodstream by the liver. Encapsulation is also more effective at penetrating the blood-brain barrier and allowing greater bioavailability and prolonging the duration of efficacy from a single dose.
About Core One Labs Inc.
Core One Labs Inc. is a technology company that licenses its technology to a state-of-the-art production and packaging facility located in Southern california. The company’s technology produces infused strips (similar to respiratory strips) which are not only a safer and healthier option compared to other forms of administration, but also superior bioavailability of the constituents of cannabis. Some bands will also include additional co-active ingredients such as nutraceuticals, vitamins, and peptides. The technology offers a new way to accurately measure the dosage and ensure the purity of the selected product. From start to finish, the production process, based on the company’s technology, tests the quality and composition of all the ingredients used in each strip, resulting in a safe, consistent and efficient delivery system. In addition, through its efforts to develop a better CannaStripsTM product, the Company has developed considerable expertise in cannabis extraction and nursery activities. The operational expertise developed by the Company as a result of these efforts has created new market opportunities for the Company in white label sales.
Core One Labs Inc.
CEO and director
FOR MORE INFORMATION PLEASE CONTACT:
The Canadian Securities Exchange has not reviewed and accepts no responsibility for the adequacy or accuracy of the contents of this press release.
The information contained in this press release contains forward-looking statements based on assumptions as of the date of this press release. These statements reflect the current estimates, beliefs, intentions and expectations of management. They are not guarantees of future performance. The Company cautions that all forward-looking statements are inherently uncertain and that actual performance may be affected by a number of important factors, many of which are beyond the control of the Company. These factors include, among others: risks and uncertainties associated with the Company’s limited operating history and the need to comply with environmental and government regulations. Additionally, marijuana remains a Schedule I drug under the United States Controlled Substances Act of 1970. Although Congress has prohibited the United States Department of Justice from spending federal funds to interfere with implementation of state medical marijuana laws, this ban must be renewed annually to remain in effect. Therefore, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Unless required by applicable securities legislation, the Company assumes no obligation to publicly update or revise forward-looking information.
SOURCE Core One Labs Inc.